[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shinshu University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":85},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100475340","phase-2-effect-of-tofogliflozin-on-uacr-compared-to-metformin-hydrochloride-in-diabetic-kidney-disease-truth-dkd-100475340",false,"NCT05469659","Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)","Effect of Tofogliflozin on Urine Albumin-to-Creatinine Ratio Compared to Metformin Hydrochloride in Diabetic Kidney Disease","TRUTH-DKD","Inclusion Criteria:\n\n* Type 2 diabetic patients\n* Patients aged 20 years or older at the time of obtaining consent\n* Patients with HbA1c 6.5 or more and 9.0% or less within 13 weeks before obtaining consent (evaluated by test values after 4 weeks or more without taking SGLT2 inhibitor \u002F metformin)\n* Patients who have been judged by their doctor to need a diabetic drug when they are first seen, or who have already taken a diabetic drug and have decided that it is necessary to add one diabetic drug.\n* Patients who have been receiving RAS inhibitors (ARB, ARNI, ACE inhibitors, direct renin inhibitors) for 4 weeks or longer\n* Patients with eGFR of 30 or more (mL \u002F min \u002F 1.73m2) within 13 weeks before obtaining consent (evaluated by test values after 4 weeks or more without taking SGLT2 inhibitor \u002F metformin)\n* Patients with urinary albumin \u002F creatinine ratio (UACR) of 30 or more and less than 2000 (mg \u002F gCr) (4 weeks or more without taking SGLT2 inhibitor \u002F metformin) within 13 weeks before obtaining consent Evaluate by inspection value)\n* Patients for whom written consent was obtained based on the patient's free will after receiving sufficient explanation for participation in this study\n\nExclusion Criteria:\n\n* Patients receiving treatment with SGLT2 inhibitor or metformin within 13 weeks before obtaining consent\n* Dialysis patient\n* Patients with a history of severe hypoglycemia\n* Patients with hypersensitivity to SGLT2 inhibitor or metformin\n* Pregnant women, lactating patients, and patients who wish to raise children\n* Patients with BMI of 35 kg \u002F m2 or more based on the latest measured values within 13 weeks before obtaining consent\n* Patients who are contraindicated for the study drug\n* Other patients who the attending physician deems inappropriate as a subject","ALL","20 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This multicenter, randomized, open-label, controlled study will assess the efficacy of the SGLT2 inhibitor tofogliflozin on Urine Albumin-to-Creatinine Ratio (UACR) compared to metformin in patients with type 2 diabetes with chronic kidney disease (CKD).",[27,28,29],"T2DM (Type 2 Diabetes Mellitus)","Metformin","SGLT2-Inhibitors","RECRUITING","2022-07-21",{"date":33,"type":34},"2022-07-22","ACTUAL",{"date":36,"type":34},"2021-09-22",{"date":38,"type":21},"2026-10-30",{"name":40,"class":41},"Shinshu University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":42},"100343711","phase-2-examination-of-efficacy-and-safety-of-other-anti-resorption-drugs-after-2-year-denosumab-therapy-in-japanese-osteoporosis-patients-100343711","NCT03755193","Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients","Examination of Efficacy and Safety of SERM or Bisphosphonates After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients","Inclusion Criteria:\n\n* osteoporosis patients\n\nExclusion Criteria:\n\n* not osteoporosis patients who are allergic to the drugs, refused to do this research, or who are pregnant","120 Years",{"count":52,"type":21},90,[24],"The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy:\n\nSERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months",[56],"Osteoporosis","2021-09-20",{"date":59,"type":34},"2021-09-21",{"date":61,"type":34},"2018-11-24",{"date":63,"type":21},"2026-11-23",{"name":40,"class":41},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":42},"100234383","non-weight-bearing-in-hip-joint-with-accompanying-joint-pain-might-not-progress-radiographic-oa-100234383","NCT02329093","Non-weight Bearing in Hip Joint With Accompanying Joint Pain Might Not Progress Radiographic OA","Inclusion Criteria:\n\n* Hip OA, Joint pain\n\nExclusion Criteria:\n\n* Obvious radipgraphic fracture in hip joint,",true,{"count":73,"type":21},100,[75],"NA","As we have previously reported, the primary cause of hip OA with accompanying joint pain might be bone alterations which can be microfracture. In order to prove it, it is planned that conservative treatment will be performed on the hip OA patients with accompanying joint pain for the first year. For the second year, if the patients still have joint pain, they will do non-weght bearing walk.",[78],"Hip OA",{"date":59,"type":34},{"date":81,"type":34},"2021-08-01",{"date":83,"type":21},"2026-11",{"name":40,"class":41},""]